Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-023740
Filing Date
2025-05-08
Accepted
2025-05-08 16:01:09
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vyne-20250331.htm   iXBRL 10-Q 733694
2 EX-31.1 vyne-20250331xexx311.htm EX-31.1 9603
3 EX-31.2 vyne-20250331xexx312.htm EX-31.2 9597
4 EX-32.1 vyne-20250331xexx321.htm EX-32.1 5510
5 EX-32.2 vyne-20250331xexx322.htm EX-32.2 5519
  Complete submission text file 0001628280-25-023740.txt   4659111

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vyne-20250331.xsd EX-101.SCH 33823
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vyne-20250331_cal.xml EX-101.CAL 52416
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vyne-20250331_def.xml EX-101.DEF 145367
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vyne-20250331_lab.xml EX-101.LAB 477857
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vyne-20250331_pre.xml EX-101.PRE 322999
66 EXTRACTED XBRL INSTANCE DOCUMENT vyne-20250331_htm.xml XML 463078
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38356 | Film No.: 25925804
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)